ATM is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for low grade ovarian serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for low grade ovarian serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS is an inclusion eligibility criterion in 2 clinical trials for low grade ovarian serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].